Hologic (HOLX)
(Delayed Data from NSDQ)
$81.39 USD
-1.01 (-1.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $81.38 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
HOLX 81.39 -1.01(-1.23%)
Will HOLX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HOLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOLX
Hologic (HOLX) Falls More Steeply Than Broader Market: What Investors Need to Know
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
HOLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term
Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term
With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?
Other News for HOLX
Critical Insights From Hologic Analyst Ratings: What You Need To Know
Hologic: A Buy Rating Amidst Temporary Challenges and Growth Potential
Hologic announces $1.5B share repurchase program
Hologic authorizes $1.5B buyback of common stock
Citi Remains a Buy on Hologic (HOLX)